

Freedom of Information request 015083 - Inflammatory Bowel Disease

25/11/19

I am writing to request the sharing of the most current information available regarding the Inflammatory Bowel Disease MDTs, and prescription of biologic drugs to treat IBD in the UK. Specifically:

1. How many members are in the MDTs within the trust, and professional makeup (ie, how many consultant gastroenterologists, clinical nurse specialists, colorectal surgeons, dietitians and other specialisations)

IBD consultant, IBD nurse specialist, IBD radiologist, surgeon, gastro consultants (up to 6) and gastro registrars.

2. Available facilities for patients with IBD in the trust (endoscopy, biologics infusion, radiography)
Endoscopy, Biologic infusion service, radiology, wireless capsule endoscopy dieticians.

3. The Trust's treatment pathway protocols for patients with moderate-to-severe ulcerative colitis (other patient treatment pathway protocols for ulcerative colitis/IBD may also be of interest)

A meeting has been arranged for next month (Dec) with Clinical Staff to review this guideline. The Trust wishes to use Exemption Section 22 - Information intended for future publication

The clinical guideline is currently under review to accommodate recent changes.

For information about the department please go to the Trust website

<http://www.dgft.nhs.uk/services-and-wards/gastroenterology/>

4. Following treatment with a biologic to induce remission, how often are patients checked up on?
Patients usually seen at 3 months by consultant and then every 6 months by consultant or IBD nurse, but they all have access to the IBD helpline should any issue occur. Patient's that attend hospital every 8 weeks for infusions can ask us to come down and review if there are any issues.

5. Please could you provide the following number of patients treated with the biologics below in the last 12 months (latest 12 months if possible), in the table below?

	Ulcerative colitis	Crohn's disease
Adalimumab	21	31
Infliximab	17	29
Golimumab - not used by IBD team		
Vedolizumab	16	10
Ustekinumab	NA	32
Tofacitinib	6	NA